Emphysema - Pipeline Insight, 2025

This “Emphysema - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Emphysema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Emphysema: Understanding

Emphysema: Overview

Emphysema is a progressive and chronic lung disease that falls under the umbrella of chronic obstructive pulmonary disease (COPD). It is characterized by the abnormal, permanent enlargement of the air spaces in the lungs, accompanied by the destruction of their walls, but notably without fibrosis. This condition leads to reduced respiratory function and airflow obstruction, making breathing increasingly difficult for affected individuals. The primary cause of emphysema is prolonged exposure to noxious particles or gases, with cigarette smoking being the most prevalent factor. The inhalation of tobacco smoke triggers inflammatory responses that progressively damage the alveoli, the tiny air sacs in the lungs, leading to their breakdown and impaired gas exchange.

Emphysema primarily presents with chronic shortness of breath (dyspnea), which worsens with physical activity and may eventually occur at rest. Patients often experience a persistent cough, which may produce sputum, and wheezing due to narrowed airways. As the disease progresses, individuals may notice a decrease in exercise tolerance, fatigue, and unintended weight loss. Advanced emphysema can lead to complications such as respiratory infections and heart problems, contributing to a decline in overall health and quality of life. In severe cases, patients may exhibit signs of respiratory distress, including rapid breathing and the use of accessory muscles for breathing. Emphysema is a chronic lung condition characterized by the destruction of the alveoli, the tiny air sacs in the lungs where gas exchange occurs. Diagnosis typically involves a combination of medical history, physical examination, and imaging tests such as chest X-rays or high-resolution computed tomography (CT) scans to visualize the extent of lung damage. Pulmonary function tests (PFTs), including spirometry, are crucial in assessing the airflow obstruction and reduced lung capacity indicative of emphysema. A thorough assessment of risk factors, such as smoking history or exposure to environmental pollutants, also aids in diagnosis. In some cases, blood tests and arterial blood gas analysis are performed to evaluate oxygen and carbon dioxide levels in the blood.

Treatment for emphysema focuses on alleviating symptoms, improving quality of life, and slowing disease progression. The cornerstone of management is smoking cessation, which significantly slows the decline in lung function. Pharmacological interventions include bronchodilators, such as short-acting and long-acting beta-agonists and anticholinergics, to relieve airflow obstruction, along with inhaled corticosteroids for patients with frequent exacerbations. Supplemental oxygen therapy is essential for those with severe hypoxemia, while pulmonary rehabilitation programs provide education, exercise training, and nutritional support to enhance overall well-being. In advanced cases, noninvasive ventilation may be necessary for acute respiratory failure, and surgical options like lung volume reduction surgery or lung transplantation can be considered for select patients. Palliative care is also important for managing symptoms and improving quality of life in later stages of the disease.

“Emphysema - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Emphysema pipeline landscape is provided which includes the disease overview and Emphysema treatment guidelines. The assessment part of the report embraces, in depth Emphysema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Emphysema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Emphysema R&D. The therapies under development are focused on novel approaches to treat/improve Emphysema.

Emphysema Emerging Drugs Chapters

This segment of the Emphysema report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Emphysema Emerging Drugs

ARO AAT: Arrowhead Pharmaceuticals

ARO AAT is a second generation, N-Acetylgalactosamine (GalNAc) based, subcutaneously administered RNA interference based therapeutic. ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. In June 2019, the US FDA has granted Fast Track designation to ARO-AAT. ARO-AAT is in Phase III clinical studies for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Alvelestat: Mereo BioPharma

Alvelestat (MPH966) is an oral drug that is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD). Alvelestat acts to inhibit the neutrophil elastase enzyme and Mereo believes that it has the potential to help protect people with AATD by slowing progressive lung damage. While AATD may affect both the lungs and the liver, alvelestat’s mechanism of action only addresses lung disease, which is the most common effect of AATD in adults. Other companies are researching the effects of AATD on the liver. Currently, the drug is in Phase II stage of its clinical trial for the treatment of emphysema.

WVE-006: Wave life Sciences

WVE-006 is a first-in-class, GalNAc-conjugated and subcutaneously administered RNA editing oligonucleotide designed to correct the single base mutation in messenger RNA (mRNA) coded by the SERPINA1 Z allele, thereby enabling restoration and circulation of functional M-AAT protein. In preclinical studies, WVE-006 demonstrated potent and durable editing of SERPINA1 Z transcript in mice, restoration of AAT protein up to 30 micromolar, and improvement in several markers of liver disease. WVE-006 is also highly specific with no evidence of bystander editing. Together, these data demonstrate the potential of WVE-006 to address AATD-related liver disease, lung disease, or both.

Emphysema: Therapeutic Assessment

This segment of the report provides insights about the different Emphysema drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Emphysema

There are approx. 18+ key companies which are developing the therapies for Emphysema. The companies which have their Emphysema drug candidates in the most advanced stage, i.e. Phase III include Arrowhead Pharmaceuticals.

Phases

The report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Emphysema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Emphysema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Emphysema therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Emphysema drugs.

Emphysema Report Insights

• Emphysema Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Emphysema Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Emphysema drugs?
• How many Emphysema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Emphysema?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Emphysema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Emphysema and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Wave Life Sciences
• Vertex Pharmaceuticals
• Takeda
• Beam Therapeutics
• Kamada
• Gain Therapeutics
• Arrowhead Pharmaceuticals

Key Products

• WVE-006
• VX-634
• Fazirsiran Injection
• BEAM-302
• Kamada AAT for inhalation
• GT 02287
• ARO AAT

This product will be delivered within 1-3 business days.